Guidelines and Good Clinical Practice Recommendations for Contrast Enhanced Ultrasound (CEUS) in the Liver - Update 2012 A WFUMB-EFSUMB Initiative in Cooperation With Representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS
diagnosis; Acoustics; radiofrequency ablation; Radiology; trial; Nuclear Medicine & Medical Imaging; hyperplasia; hemangioma; hepatocellular carcinoma; metastases; colorectal-cancer; b-mode; degum multicenter; focal nodular; gastrointestinal stromal tumors; guided; hepatic-artery thrombosis; intraoperative ultrasonography; microbubble; peripheral cholangiocarcinoma; quantitative assessment; small hepatocellular-carcinoma
Initially, a set of guidelines for the use of ultrasound contrast agents was published in 2004 dealing only with liver applications. A second edition of the guidelines in 2008 reflected changes in the available contrast agents and updated the guidelines for the liver, as well as implementing some non-liver applications. Time has moved on, and the need for international guidelines on the use of CEUS in the liver has become apparent. The present document describes the third iteration of recommendations for the hepatic use of contrast enhanced ultrasound (CEUS) using contrast specific imaging techniques. This joint WFUMB-EFSUMB initiative has implicated experts from major leading ultrasound societies worldwide. These liver CEUS guidelines are simultaneously published in the official journals of both organizing federations (i.e., Ultrasound in Medicine and Biology for WFUMB and Ultraschall in der Medizin/European Journal of Ultrasound for EFSUMB). These guidelines and recommendations provide general advice on the use of all currently clinically available ultrasound contrast agents (UCA). They are intended to create standard protocols for the use and administration of UCA in liver applications on an international basis and improve the management of patients worldwide.
Claudon M; Dietrich C F; Choi B I; Cosgrove D O; Kudo M; Nolsoe C P; Piscaglia F; Wilson S R; Barr R G; Chammas M C; Chaubal N G; Chen M H; Clevert D A; Correas J M; Ding H; Forsberg F; Fowlkes J B; Gibson R N; Goldberg B B; Lassau N; Leen E L S; Mattrey R F; Moriyasu F; Solbiati L; Weskott H P; Xu H X
Ultraschall in Der Medizin
2013
2013-02
Journal Article or Conference Abstract Publication
<a href="http://doi.org/10.1055/s-0032-1325499" target="_blank" rel="noreferrer noopener">10.1055/s-0032-1325499</a>
Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) in the liver - update 2020 - WFUMB in cooperation with EFSUMB, AFSUMB, AIUM, and FLAUS.
The present, updated document describes the fourth iteration of recommendations for the hepatic use of contrast enhanced ultrasound (CEUS), first initiated in 2004 by the European Federation of Societies for Ultrasound in Medicine and Biology (EFSUMB). The previous updated editions of the guidelines reflected changes in the available contrast agents and updated the guidelines not only for hepatic but also for non-hepatic applications.The 2012 guideline requires updating as previously the differences of the contrast agents were not precisely described and the differences in contrast phases as well as handling were not clearly indicated. In addition, more evidence has been published for all contrast agents. The update also reflects the most recent developments in contrast agents, including the United States Food and Drug Administration (FDA) approval as well as the extensive Asian experience, to produce a truly international perspective.These guidelines and recommendations provide general advice on the use of ultrasound contrast agents (UCA) and are intended to create standard protocols for the use and administration of UCA in liver applications on an international basis to improve the management of patients.
Dietrich CF; Nolsøe CP; Barr RG; Berzigotti A; Burns PN; Cantisani V; Chammas MC; Chaubal N; Choi BI; Clevert D; Cui X; Dong Y; D'Onofrio M; Fowlkes JB; Gilja OH; Huang P; Ignee Andre; Jenssen C; Kono Y; Kudo M; Lassau N; Lee WJ; Lee JY; Liang P; Lim A; Lyshchik A; Meloni MF; Correas JM; Yasunori M; Moriyasu F; Nicolau C; Piscaglia F; Saftoiu A; Sidhu PS; Sporea I; Torzilli G; Xie X; Zheng R
Ultraschall in der Medizin (Stuttgart, Germany : 1980)
2020
2020-07-24
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
journalArticle
<a href="http://doi.org/10.1055/a-1177-0530" target="_blank" rel="noreferrer noopener">10.1055/a-1177-0530</a>
Guidelines and good clinical practice recommendations for contrast-enhanced ultrasound (CEUS) in the liver-update 2020 WFUMB in cooperation with EFSUMB, AFSUMB, AIUM, and FLAUS.
Liver; World Federation for Ultrasound in Medicine and Biology; Contrast-enhanced ultrasound; Guideline
The present, updated document describes the fourth iteration of recommendations for the hepatic use of contrast-enhanced ultrasound, first initiated in 2004 by the European Federation of Societies for Ultrasound in Medicine and Biology. The previous updated editions of the guidelines reflected changes in the available contrast agents and updated the guidelines not only for hepatic but also for non-hepatic applications. The 2012 guideline requires updating as, previously, the differences in the contrast agents were not precisely described and the differences in contrast phases as well as handling were not clearly indicated. In addition, more evidence has been published for all contrast agents. The update also reflects the most recent developments in contrast agents, including U.S. Food and Drug Administration approval and the extensive Asian experience, to produce a truly international perspective. These guidelines and recommendations provide general advice on the use of ultrasound contrast agents (UCAs) and are intended to create standard protocols for the use and administration of UCAs in liver applications on an international basis to improve the management of patients.
Dietrich CF; Nolsøe CP; Barr RG; Berzigotti A; Burns PN; Cantisani V; Chammas MC; Chaubal N; Choi BI; Clevert D; Cui X; Dong Y; D'Onofrio M; Fowlkes JB; Gilja OH; Huang P; Ignee Andre; Jenssen C; Kono Y; Kudo M; Lassau N; Lee WJ; Lee JY; Liang P; Lim A; Lyshchik A; Meloni MF; Correas JM; Yasunori M; Moriyasu F; Nicolau C; Piscaglia F; Saftoiu A; Sidhu PS; Sporea I; Torzilli G; Xie X; Zheng R
Ultrasound in Medicine & Biology
2020
2020-07-22
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
journalArticle
<a href="http://doi.org/10.1016/j.ultrasmedbio.2020.04.030" target="_blank" rel="noreferrer noopener">10.1016/j.ultrasmedbio.2020.04.030</a>
Guidelines and good clinical practice recommendations for contrast-enhanced ultrasound (CEUS) in the liver-update 2020 WFUMB in cooperation with EFSUMB, AFSUMB, AIUM, and FLAUS.
World Federation for Ultrasound in Medicine and Biology; Liver; Contrast-enhanced ultrasound; Guide-line; Guideline
The present, updated document describes the fourth iteration of recommendations for the hepatic use of contrast-enhanced ultrasound, first initiated in 2004 by the European Federation of Societies for Ultrasound in Medicine and Biology. The previous updated editions of the guidelines reflected changes in the available contrast agents and updated the guidelines not only for hepatic but also for non-hepatic applications. The 2012 guideline requires updating as, previously, the differences in the contrast agents were not precisely described and the differences in contrast phases as well as handling were not clearly indicated. In addition, more evidence has been published for all contrast agents. The update also reflects the most recent developments in contrast agents, including U.S. Food and Drug Administration approval and the extensive Asian experience, to produce a truly international perspective. These guidelines and recommendations provide general advice on the use of ultrasound contrast agents (UCAs) and are intended to create standard protocols for the use and administration of UCAs in liver applications on an international basis to improve the management of patients.
Dietrich CF;Nolsøe CP;Barr RG;Berzigotti A;Burns PN;Cantisani V;Chammas MC;Chaubal N;Choi BI;Clevert D-A;Cui X;Dong Y;D'Onofrio M;Fowlkes JB;Gilja OH;Huang P;Ignee A;Jenssen C;Kono Y;Kudo M;Lassau N;Lee WJ;Lee JY;Liang P;Lim A;Lyshchik A;Meloni MF;Correas JM;Minami Y;Moriyasu F;Nicolau C;Piscaglia F;Saftoiu A;Sidhu PS;Sporea I;Torzilli G;Xie X;Zheng R
Ultrasound in Medicine & Biology
2020
2020-10
journalArticle
<a href="http://doi.org/10.1016/j.ultrasmedbio.2020.04.030" target="_blank" rel="noreferrer noopener">10.1016/j.ultrasmedbio.2020.04.030</a>
Quantification of Liver Fat Content with Ultrasound: A WFUMB Position Paper.
Attenuation coefficient; Backscatter; Controlled attenuation parameter; Dispersion; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Quantitative ultrasound; Speed of sound
New ultrasound methods that can be used to quantitatively assess liver fat content have recently been developed. These quantitative ultrasound (QUS) methods are based on the analysis of radiofrequency echoes detected by the transducer, allowing calculation of parameters for quantifying the fat in the liver. In this position paper, after a section dedicated to the importance of quantifying liver steatosis in patients with non-alcoholic fatty liver disease and another section dedicated to the assessment of liver fat with magnetic resonance, the current clinical studies performed using QUS are summarized. These new methods include spectral-based techniques and techniques based on envelope statistics. The spectral-based techniques that have been used in clinical studies are those estimating the attenuation coefficient and those estimating the backscatter coefficient. Clinical studies that have used tools based on the envelope statistics of the backscattered ultrasound are those performed by using the acoustic structure quantification or other parameters derived from it, such as the normalized local variance, and that performed by estimating the speed of sound. Experts' opinions are reported. (Copyright © 2021 World Federation for Ultrasound in Medicine & Biology. Published by Elsevier Inc. All rights reserved.)
Ferraioli G; Berzigotti A; Barr RG; Choi BI; Cui XW; Dong Y; Gilja OH; Lee JY; Lee DH; Moriyasu F; Piscaglia F; Sugimoto K; Wong GL; Wong VW; Dietrich CF
Ultrasound in Medicine & Biology
2021
2021-07-17
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
journalArticle
<a href="http://doi.org/10.1016/j.ultrasmedbio.2021.06.002" target="_blank" rel="noreferrer noopener">10.1016/j.ultrasmedbio.2021.06.002</a>